Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (31-40 of 198) with videos related to

Pageof 20
Sort By:
Internal Medicine Journal|November 26, 2024
A review and recommendations on the management of psoriatic arthritis in Australia 2024Peter Nash, Daniel Sumpton, Michelle Tellus, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatmentRieke Alten, Jeffrey Kaine, Edward Keystone, et al.
Arthritis and Rheumatism|January 20, 2004
Assessment of patients with psoriatic arthritis: a review of currently available measuresDafna D Gladman, Philip Helliwell, Philip J Mease, et al.
The Journal of Rheumatology|July 9, 2008
Initiative for quality in psoriasis and psoriatic arthritisWolf-Henning Boehncke, Ade Adebajo, Alberto Cauli, et al.
The Journal of Rheumatology|November 3, 2014
Updated guidelines for the management of axial disease in psoriatic arthritisPeter Nash, Ennio Lubrano, Alberto Cauli, et al.
RMD Open|March 20, 2019
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinibPaul Bird, Stephen Hall, Peter Nash, et al.
Clinical and Experimental Rheumatology|September 8, 2021
Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 studyPeter Nash, Philip J Mease, Bruce Kirkham, et al.
Therapeutic Advances in Musculoskeletal Disease|October 24, 2024
What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?Peter C Taylor, Eugen Feist, Janet E Pope, et al.
Clinical Rheumatology|September 12, 2021
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trialsAlan J Kivitz, Oliver FitzGerald, Peter Nash, et al.
Lancet (London, England)|September 5, 2006
Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trialDaina Vanags, Bronwyn Williams, Barbara Johnson, et al.
Pageof 20

Showing results (31-40 of 198) with videos related to

Sort By:
Pageof 20
Internal Medicine Journal|November 26, 2024
A review and recommendations on the management of psoriatic arthritis in Australia 2024Peter Nash, Daniel Sumpton, Michelle Tellus, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatmentRieke Alten, Jeffrey Kaine, Edward Keystone, et al.
Arthritis and Rheumatism|January 20, 2004
Assessment of patients with psoriatic arthritis: a review of currently available measuresDafna D Gladman, Philip Helliwell, Philip J Mease, et al.
The Journal of Rheumatology|July 9, 2008
Initiative for quality in psoriasis and psoriatic arthritisWolf-Henning Boehncke, Ade Adebajo, Alberto Cauli, et al.
The Journal of Rheumatology|November 3, 2014
Updated guidelines for the management of axial disease in psoriatic arthritisPeter Nash, Ennio Lubrano, Alberto Cauli, et al.
RMD Open|March 20, 2019
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinibPaul Bird, Stephen Hall, Peter Nash, et al.
Clinical and Experimental Rheumatology|September 8, 2021
Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 studyPeter Nash, Philip J Mease, Bruce Kirkham, et al.
Therapeutic Advances in Musculoskeletal Disease|October 24, 2024
What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?Peter C Taylor, Eugen Feist, Janet E Pope, et al.
Clinical Rheumatology|September 12, 2021
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trialsAlan J Kivitz, Oliver FitzGerald, Peter Nash, et al.
Lancet (London, England)|September 5, 2006
Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trialDaina Vanags, Bronwyn Williams, Barbara Johnson, et al.
Pageof 20